Satisfaction and Adherence in Patients with Iron Overload Receiving Iron Chelation Therapy as Assessed by a Newly Developed Patient Instrument

被引:25
|
作者
Rofail, Diana [1 ]
Abetz, Linda [1 ]
Viala, Muriel [3 ]
Gait, Claire [1 ]
Baladi, Jean-Francois [2 ]
Payne, Krista [4 ]
机构
[1] Mapi Values, Bollington SK10 5JB, Cheshire, England
[2] Novartis Pharmaceut, E Hanover, NJ USA
[3] Mapi Values, Lyon, France
[4] Caro Res, Montreal, PQ, Canada
关键词
adherence; instrument; iron chelation therapy; oral administration; satisfaction; SICT; subcutaneous administration; QUALITY-OF-LIFE; THALASSEMIA MAJOR; BETA-THALASSEMIA; IMPACT; CARE; DEFEROXAMINE; SAFETY; BURDEN;
D O I
10.1111/j.1524-4733.2008.00390.x
中图分类号
F [经济];
学科分类号
02 ;
摘要
This study assesses satisfaction with iron chelation therapy (ICT) based on a reliable and valid instrument, and explores the relationship between satisfaction and adherence to ICT. Patients in the USA and UK completed a new "Satisfaction with ICT" (SICT) instrument consisting of 28 items, three pertaining to adherence. Simple and multivariate regression analyses assessed the relationship between satisfaction with different aspects of ICT and adherence. First assessments of the SICT instrument indicate its validity and reliability. Recommended thresholds for internal consistency, convergent validity, discriminant validity, and floor and ceiling effects were met. A number of variables were identified in the simple linear regression analyses as significant predictors of "never thinking about stopping ICT," a proxy for adherence. These significant variables were entered into the multivariate model to assess the combined factor effects, explaining 42% of the total variance of "never thinking about stopping ICT." A significant and positive relationship was demonstrated between "never thinking about stopping ICT" and age (P = 0.04), Perceived Effectiveness of ICT (P = 0.003), low Burden of ICT (P = 0.002), and low Side Effects of ICT (P = 0.01). The SICT is a reliable and valid instrument which will be useful in ICT clinical trials. Furthermore, the administration of ICT by slow subcutaneous infusion negatively impacts on satisfaction with ICT which was shown to be a determinant of adherence. This points to the need for new more convenient and less burdensome oral iron chelators to increase adherence, and ultimately to improve patient outcomes.
引用
收藏
页码:109 / 117
页数:9
相关论文
共 50 条
  • [1] An instrument assessing satisfaction with iron chelation therapy: Psychometric testing from an open-label clinical trial
    Rofail, Diana
    Viala, Muriel
    Gater, Adam
    Abetz-Webb, Linda
    Baladi, Jean-Francois
    Cappellini, Maria Domenica
    ADVANCES IN THERAPY, 2010, 27 (08) : 533 - 546
  • [2] Iron chelation therapy for patients with sickle cell disease and iron overload
    Inati, Adlette
    Khoriaty, Evelyne
    Musallam, Khaled M.
    Taher, Ali T.
    AMERICAN JOURNAL OF HEMATOLOGY, 2010, 85 (10) : 782 - 786
  • [3] Clinical consequences of iron overload in patients with myelodysplastic syndromes: the case for iron chelation therapy
    Shammo, Jamile M.
    Komrokji, Rami S.
    EXPERT REVIEW OF HEMATOLOGY, 2018, 11 (07) : 577 - 586
  • [4] Patient Perspective on Iron Chelation Therapy: Barriers and Facilitators of Medication Adherence
    Chong, Chia Chee
    Redzuan, Adyani Md
    Sathar, Jameela
    Makmor-Bakry, Mohd
    JOURNAL OF PATIENT EXPERIENCE, 2021, 8
  • [5] Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload
    Gattermann, Norbert
    LEUKEMIA RESEARCH, 2007, 31 : S10 - S15
  • [6] The challenges of adherence and persistence with iron chelation therapy
    Porter, John B.
    Evangeli, Michael
    El-Beshlawy, Amal
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2011, 94 (05) : 453 - 460
  • [7] IRON CHELATION THERAPY FOR TRANSFUSIONAL IRON OVERLOAD: A SWIFT EVOLUTION
    Musallam, Khaled M.
    Taher, Ali T.
    HEMOGLOBIN, 2011, 35 (5-6) : 565 - 573
  • [8] Iron overload and chelation therapy in myelodysplastic syndromes
    Temraz, Sally
    Santini, Valeria
    Musallam, Khaled
    Taher, Ali
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2014, 91 (01) : 64 - 73
  • [9] Improvement of chronic hepatitis B by iron chelation therapy in a patient with iron overload: A case report
    Zou, Dong-Mei
    Rong, Dong-Dong
    Zhao, Hong
    Su, Li
    Sun, Wan-Ling
    MEDICINE, 2017, 96 (52)
  • [10] The Relevance of Iron Overload and the Appropriateness of Iron Chelation Therapy for Patients with Myelodysplastic Syndromes: A Dialogue and Debate
    Steensma, David P.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2011, 6 (02) : 136 - 144